Goldline Pharmaceutical Limite (BSE: 544759) is a Nagpur, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹29 Cr, it ranks #4,082 by market cap among the 6,197 Indian listed companies on FinBizNet, and #55 of 63 in Pharmaceuticals. At ₹29.70 (as of 10 Nov 2026), the share price is 50.5% below its 52-week high of ₹60.00 and 5.6% above its 52-week low of ₹28.13.
| Current Price | ₹29.70 |
|---|---|
| Market Cap | ₹29 Cr |
| BSE Code | 544759 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 5 |
| Return on Assets | 15.50% |
| 52-Week Range | ₹28.13 – ₹60.00 |
| 3-Month Price Change | -28.0% |
| Beta (1Y) | -0.01 |
| Headquarters | Nagpur, Maharashtra |
| Website | goldlinepharma.in |
Delivery averaged 91.2% of traded volume across 12 BSE sessions (15 Oct 2026 – 5 Nov 2026).
Goldline Pharmaceutical Limited engages in marketing of pharmaceutical products under the Goldline brand in India. It offers goldline pharma, goldline cardinal, goldline aayushman, goldline inLife, and goldline wellness. The company serves physicians, orthopedics, ENT, chest physicians, general and specialty surgery, gastroenterology, neurology, urology, endocrinologists, cardiologists, general physicians, pediatricians, child specialists, neonatologists, intensivists, critical care consultants, and super specialty surgeons. It sells its products through distributors. The company was incorporated in 2004 and is based in Nagpur, India.
1. Selling and Distribution of Medicines-This segment engages in the marketing of pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Selling and Distribution of Medicines-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹54,788 Cr | 35.3 | 34.46% | ₹1,814 Cr | -8.2% |
| Ajanta Pharma Limited | ₹42,432 Cr | 40.2 | 25.39% | ₹1,794 Cr | +35.7% |
| Emcure Pharmaceuticals Ltd | ₹35,726 Cr | 38.6 | 19.57% | ₹2,820 Cr | +67.0% |
| Piramal Pharma Ltd | ₹31,892 Cr | n/m | -4.00% | ₹2,617 Cr | +21.7% |
| RUBICON RESEARCH LIMITED | ₹27,601 Cr | 108.9 | 19.14% | ₹576 Cr | +186.9% |
| Caplin Point Laboratories Ltdte | ₹17,770 Cr | 27.8 | 19.94% | ₹610 Cr | +25.0% |
| Pfizer Ltd. | ₹16,646 Cr | 23 | 17.16% | ₹727 Cr | -24.3% |
| Eris Lifesciences Ltd | ₹16,096 Cr | 25.6 | 18.07% | ₹892 Cr | -21.1% |
| Goldline Pharmaceutical Limite | ₹29 Cr | 5 | — | — | — |
Listed by market capitalisation. Ratios are shown for context only.
Goldline Pharmaceutical Limite is trading at ₹29.70, with a market capitalisation of ₹29 Cr.
Goldline Pharmaceutical Limite operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Goldline Pharmaceutical Limite has a P/E of 5.
Goldline Pharmaceutical Limite is listed on the BSE under the scrip code 544759.
Data as of 10 Nov 2026. Descriptive market data only — not investment advice.